Baricitinib is safe and effective for treatment of refractory juvenile idiopathic arthritis
1. Time to disease flare was significantly shorter in the placebo group versus baricitinib. 2. There was no difference in ...
1. Time to disease flare was significantly shorter in the placebo group versus baricitinib. 2. There was no difference in ...
1. Patients in the tofacitinib group reported significantly fewer flare-ups (29%) compared to placebo (53%) by week 44. 2. The ...
1. Patients in the tofacitinib group reported significantly fewer flare-ups (29%) compared to placebo (53%) by week 44. 2. The ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.